Tysabri has 14,000 patients a year after re-launch

Share this article:

An estimated 14,000 patients across the globe are currently taking Elan and Biogen IDEC's multiple sclerosis treatment Tysabri, a year after the drug's return to market.

In the US, over 8,600 patients are on Tysabri and over 1,800 physicians have prescribed the therapy, the drug's marketers said. In the European Union, over 4,300 patients are on Tysabri therapy. An additional 1,000 patients are taking the drug in global clinical trials.

An FDA panel allowed Tysabri back on the market in June 2006 under a restricted distribution program. The agency ruled that Tysabri could only be prescribed, distributed and infused by healthcare providers registered with the “Tysabri Outreach: Unified Commitment to Health (TOUCH) prescribing program.” Before Tysabri treatment can start, patients must undergo a magnetic resonance imaging (MRI) scan. Then, patients on Tysabri are to be evaluated at three and six months after the first infusion, and every six months after that, with their status being reported directly to Biogen IDEC.

Tysabri was initially approved by the FDA in November 2004, but was withdrawn by Biogen Idec and Elan in February 2005, after three patients in the drug's clinical trials developed PML, a serious and rare viral infection of the brain. Based on this information, FDA put clinical trials of the drug on hold in February 2005.

FDA allowed a clinical trial of Tysabri to resume in February 2006, following a re-examination of the patients who had participated in the previous clinical trials, confirming that there were no additional cases of PML.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.